Speakers
Jessica Kirshner
Senior Director of Oncology
Regeneron Pharmaceuticals
Day One
Wednesday, June 30, 2021
6:30 pm | Chair’s Closing Remarks
Alison Crawford
Associate Director of Immuno-oncology
Regeneron
Pre-Conference Workshop
June 29, 2021
12:05 pm | Speaker Q&A
11:15 am | Examining Toxicity Mitigation Strategies To CD3 Bispecifics In Humanized Mouse Models
Laurent Gauthier
Senior Director
Innate Pharma
Day One
Wednesday, June 30, 2021
11:00 am | Multi-functional Natural Killer Cell Engagers
12:15 pm | Live Q&A - Ask our Speakers Your Burning Questions
Imaj Ajjawi
VP of Business Development
Absci
Marta Germani
Research Analyst
Beacon Targeted Therapies
Day One
Wednesday, June 30, 2021
8:05 am | Landscape Review of CD3 Bispecifics
9:35 am | Live Q&A - Ask our Speakers Your Burning Questions
Eric Vivier
Chief Scientific Officer
Innate Pharma
Mohamed Elmeliegy
Associate Director Clinical Pharmacology
Pfizer
Day Two
Thursday, July 1, 2021
8:05 am | Chair’s Opening Remarks
Pre-Conference Workshop
June 29, 2021
12:45 pm | Round Table: Developing A Dosing Strategy For Clinical Trial Investigations
Matthew Weinstock
Chief Technology Officer
Absci
Day One
Wednesday, June 30, 2021
9:20 am | Absci's Revolutionary Approach to Discovering Novel T-Cell Engagers in Scalable Manufacturing Cell Lines
9:35 am | Live Q&A - Ask our Speakers Your Burning Questions
Erin Meermeier
Senior Research Fellow
Mayo Clinic
Pre-Conference Workshop
June 29, 2021
1:45 pm | Developing Combination Approaches Using Immunocompetent Vk*MYChCRBN Genetically Engineered Humanized Model Of Multiple Myeloma
Maya Kotturi
Director of Preclinical Biomarkers
IGM Biosciences
Pre-Conference Workshop
June 29, 2021
2:10 pm | Developing A Preclinical Biomarker Strategy For Assessing Efficacy and Safety of Bispecific T Cell Engagers
Peter Pavlik
Director of Molecular Biology and Antibody Engineering
Aptevo Therapeutics
Day One
Wednesday, June 30, 2021
10:35 am | Live Q&A - Ask our Speakers Your Burning Questions
9:45 am | Engineering of APVO442, a bispecific molecule with high affinity tumor targeting and low affinity binding to CD3 to potentially improve efficacy in solid tumors
Oren Bogin
Chief Executive Officer
Immunorizon
Day Two
Thursday, July 1, 2021
5:00 pm | Chair’s Closing Remarks
Catherine McMahan
Senior Director of Pharmacology & Cell Sciences
Aptevo Therapeutics
Day Two
Thursday, July 1, 2021
11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates
Hilario Ramos
Senior Director of Immuno-Biology
Aptevo Therapeutics
Day One
Wednesday, June 30, 2021
4:00 pm | APVO603: A distinct dual agonistic bispecific approach to facilitate anti-tumor activity and overcome limitations of monoclonal OX-40 and 4-1BB targeting
4:25 pm | Live Q&A - Ask our Speakers Your Burning Questions
Chris Hughes
CSO
Aracari Biosciences
Day One
Wednesday, June 30, 2021
12:45 pm | Live Q&A - Ask our Speakers Your Burning Questions
12:30 pm | The Promise of Vascularized Micro-Organs & Tumors for Drug Discovery
James Keck
Senior Director, Innovation and Product Development
The Jackson Laboratory
Day Two
Thursday, July 1, 2021
11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates
11:00 am | De-risking Therapeutic Antibody Preclinical Drug Development: Simultaneous Assessment of Efficacy and Toxicity in Humanized Mice
Suhasini Iyer
Chief Development Officer
TeneoBio
Day Two
Thursday, July 1, 2021
11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates
Pieter Fokko van Loo
Senior Director, Oncology - Immunology
Merus
Day One
Wednesday, June 30, 2021
12:15 pm | Live Q&A - Ask our Speakers Your Burning Questions
11:25 am | Triclonics™ ENGAGE: Trispecific Antibody Platform for Tumor Specific T-Cell Engagers
Christian Klein
Department Head Cancer Immunotherapy Discovery
Roche
Day One
Wednesday, June 30, 2021
9:35 am | Live Q&A - Ask our Speakers Your Burning Questions
8:30 am | Novel Approaches for T-Cell Engagement
Bryan Irving
Chief Scientific Officer
Amunix Pharmaceuticals
Andrew Pierce
VP Translational Biology
Crescendo Biologics
Day One
Wednesday, June 30, 2021
3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions
2:30 pm | CB307 Tri-Partite Humabody® Enhances T-Cells Through PSMA-Dependent CD137 (4-1BB) Agonism
Nelly Kuklin
VP Immunology
Compass Therapeutics
Day One
Wednesday, June 30, 2021
12:15 pm | Live Q&A - Ask our Speakers Your Burning Questions
11:50 am | Bispecific Anti-PD-1/PD-L1 Antibody CTX-8371 Promotes Immunological Synapse Formation & PD-1 Shedding With Superior Anti-Tumor Activity & Favorable Tolerability
Yiping Rong
Head of Discovery Biology
Harbour Biomed
Day One
Wednesday, June 30, 2021
4:25 pm | Live Q&A - Ask our Speakers Your Burning Questions
3:35 pm | HBICETM-Based B7H4x4-1BB Bispecific Provides Tumor Specific 2nd Costimulatory Signal & Anti-Tumor Immune Response
Nicholas Huntington
Co-Founder & Chief Scientific Officer
oNKo-innate
Day Two
Thursday, July 1, 2021
3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions
2:05 pm | Tuning the NK Cell Response to Soluble Factors in the Tumor Microenvironment
Tatiana Novobrantseva
Co-Founder & Chief Scientific Officer
Verseau Therapeutics
Day Two
Thursday, July 1, 2021
3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions
2:30 pm | Macrophage Repolarization as a Key Strategy in Changing Tumor Microenvironment
Saileta Prabhu
VP/Global Head, Clinical Biomarker Innovation & Development
Takeda
Day Two
Thursday, July 1, 2021
4:50 pm | Live Q&A - Ask our Speakers Your Burning Questions
4:00 pm | ROI on Clinical Biomarkers, CDx and Precision Medicine
David DiLillo
Associate Director
Regeneron Pharmaceuticals
Day One
Wednesday, June 30, 2021
10:35 am | Live Q&A - Ask our Speakers Your Burning Questions
10:10 am | Benchmarking T-cell -Redirecting Therapies for Cancer: Comparing Bispecifics & CAR T Cells
Patricia Giblin
VP of Biology
Revitope Oncology
Day Two
Thursday, July 1, 2021
11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates
10:50 am | Live Q&A - Ask our Speakers Your Burning Questions
10:00 am | Improving the Therapeutic Index with Guided Antibody Tumor Engagers (GATETM)
Lily Pao
Head of Immuno- Oncology Cluster, Immuno-Oncology Therapeutic Area
Sanofi
Day Two
Thursday, July 1, 2021
8:15 am | Multispecific Immune Cell Engagers for Cancer Immunotherapy
9:30 am | Live Q&A - Ask our Speakers Your Burning Questions
Floris van Delft
Chief Scientific Officer
Synaffix
Day Two
Thursday, July 1, 2021
9:30 am | Live Q&A - Ask our Speakers Your Burning Questions
9:05 am | Generation of Bispecific & Trispecific T-Cell & NK Cell- Engagers From Any IgG Without Prior Reengineering
Fernanda Arnaldez
Executive Director - Medical & Global Clinical Development
MacroGenics
Wim van Schooten
Chief Scientific Officer
TeneoBio
Day Two
Thursday, July 1, 2021
1:55 pm | Live Q&A - Ask our Speakers Your Burning Questions
1:30 pm | Safety & Efficacy of T-Cell Engagers with Low Agonist Activity in Oncology & Infectious Diseases
Chad May
SVP Research & Development
Maverick Therapeutics
Day One
Wednesday, June 30, 2021
1:20 pm | Panel Discussion: Mitigation Against On-Target, Off Tumor
Brian Rabinovich
Director
EMD Serono
Day One
Wednesday, June 30, 2021
1:20 pm | Panel Discussion: Mitigation Against On-Target, Off Tumor
Lukas Roth
Senior Scientist, Protein Engineering and Antibody Technologies
Merck KGaA
Day One
Wednesday, June 30, 2021
6:15 pm | Live Q&A - Ask our Speakers Your Burning Questions
5:00 pm | Affinity Maturation of B7-H6 Translates Into Enhanced NK Cell-Mediated Tumor Cell Lysis & Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement
Michael Hedvat
Associate Director
Xencor
Day One
Wednesday, June 30, 2021
3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions
2:55 pm | Tumor-Targeted CD28 Costimulatory Bispecific Antibodies Enhance T-Cell Activation in Solid Tumors
Joachim Koch
Head of Translational Research & Innovation
Affimed GmbH
Day One
Wednesday, June 30, 2021
6:15 pm | Live Q&A - Ask our Speakers Your Burning Questions
5:50 pm | Combination Therapies with Innate Cell Engagers to Fight for Patients in Need
Julie Bailis
Director of Research
Amgen
Day One
Wednesday, June 30, 2021
9:35 am | Live Q&A - Ask our Speakers Your Burning Questions
8:55 am | Targeting Prostate Cancer with T-Cell Engager Immune Therapies
Day Two
Thursday, July 1, 2021
11:30 am | Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates
Janet Peper
Senior Scientist, Translational Science
Pieris Pharmaceuticals
Day One
Wednesday, June 30, 2021
2:05 pm | Tumor-localized 4-1BB Agonism in Immuno-Oncology
3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions
Divya Mathur
Director of Immuno-oncology
Regeneron Pharmaceuticals
Day One
Wednesday, June 30, 2021
1:20 pm | Panel Discussion: Mitigation Against On-Target, Off Tumor
8:00 am | Opening address from chair
Nuzhat Pathan
Senior Director, Translational and Immuno-Oncology
Pfizer
Day Two
Thursday, July 1, 2021
4:50 pm | Live Q&A - Ask our Speakers Your Burning Questions
4:25 pm | Biomarker strategies for optimal Immuno-Oncology combinations
Danielle Dettling
Senior Director, Pre- Clinical Pharmacology
Maverick Therapeutics
Day Two
Thursday, July 1, 2021
10:25 am | Utilizing its conditionally activated COBRA platform in the solid tumor space to demonstrate an improved therapeutic window over conventional T-cell engagers
10:50 am | Live Q&A - Ask our Speakers Your Burning Questions
Gosia Nocula-Lugowska
Principal Scientist
Pfizer
Day Two
Thursday, July 1, 2021
8:40 am | Optimizing T-cell Bispecifics in the Treatment of Solid Tumors
9:30 am | Live Q&A - Ask our Speakers Your Burning Questions
Pre-Conference Workshop
June 29, 2021
12:05 pm | Speaker Q&A
11:40 am | Review Types and Sources of Toxicity for T-Cell Retargeting Bi and Multi-Specific Antibodies
Rick Austin
Vice President, Research
Harpoon Therapeutics
Day Two
Thursday, July 1, 2021
3:20 pm | Live Q&A - Ask our Speakers Your Burning Questions
2:55 pm | Presentation Title To Be Announced
Hans van der Vliet
CSO
Lava Therapeutics
Day One
Wednesday, June 30, 2021
6:15 pm | Live Q&A - Ask our Speakers Your Burning Questions
5:25 pm | Bispecific Antibodies to Engage Vγ9Vδ2-T Cells for Cancer Immunotherapy
Bruce Keyt
Chief Scientific Officer
IGM Biosciences
Day One
Wednesday, June 30, 2021
1:20 pm | Panel Discussion: Mitigation Against On-Target, Off Tumor
Day Two
Thursday, July 1, 2021